{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:32:47Z","timestamp":1773869567153,"version":"3.50.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40263-020-00727-3","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T14:02:36Z","timestamp":1590760956000},"page":"559-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0899-3030","authenticated-orcid":false,"given":"Claire","family":"Henchcliffe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harini","family":"Sarva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"issue":"5","key":"727_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.stem.2017.09.014","volume":"21","author":"RA Barker","year":"2017","unstructured":"Barker RA, Parmar M, Studer L, Takahashi J. Human trials of stem cell-derived dopamine neurons for Parkinson\u2019s disease: dawn of a new era. Cell Stem Cell. 2017;21(5):569\u201373. https:\/\/doi.org\/10.1016\/j.stem.2017.09.014.","journal-title":"Cell Stem Cell"},{"issue":"s1","key":"727_CR2","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.3233\/JPD-181488","volume":"8","author":"C Henchcliffe","year":"2018","unstructured":"Henchcliffe C, Parmar M. Repairing the brain: cell replacement using stem cell-based technologies. J Parkinsons Dis. 2018;8(s1):S131\u20137. https:\/\/doi.org\/10.3233\/JPD-181488.","journal-title":"J Parkinsons Dis."},{"issue":"1","key":"727_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020;36(1):11\u20132. https:\/\/doi.org\/10.1016\/j.cger.2019.08.002.","journal-title":"Clin Geriatr Med"},{"issue":"1","key":"727_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27(1):27\u201342. https:\/\/doi.org\/10.1111\/ene.14108.","journal-title":"Eur J Neurol"},{"issue":"4","key":"727_CR5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1212\/CON.0000000000000764","volume":"25","author":"TA Zesiewicz","year":"2019","unstructured":"Zesiewicz TA. Parkinson disease. Continuum (Minneap Minn). 2019;25(4):896\u2013918. https:\/\/doi.org\/10.1212\/CON.0000000000000764.","journal-title":"Continuum (Minneap Minn)."},{"issue":"8","key":"727_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33(8):1248\u201366. https:\/\/doi.org\/10.1002\/mds.27372.","journal-title":"Mov Disord"},{"issue":"9","key":"727_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/mds.27809","volume":"34","author":"P Fishman","year":"2019","unstructured":"Fishman P, Lipsman N. Focused ultrasound as an evolving therapy for Parkinson\u2019s disease. Mov Disord. 2019;34(9):1241\u20132. https:\/\/doi.org\/10.1002\/mds.27809.","journal-title":"Mov Disord"},{"key":"727_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.parkreldis.2019.07.018","volume":"66","author":"FL Hitti","year":"2019","unstructured":"Hitti FL, Yang AI, Gonzalez-Alegre P, Baltuch GH. Human gene therapy approaches for the treatment of Parkinson\u2019s disease: an overview of current and completed clinical trials. Parkinsonism Relat Disord. 2019;66:16\u201324. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.07.018.","journal-title":"Parkinsonism Relat Disord."},{"issue":"12","key":"727_CR9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/14712598.2018.1546840","volume":"18","author":"CR Marques","year":"2018","unstructured":"Marques CR, Marote A, Mendes-Pinheiro B, Teixeira FG, Salgado AJ. Cell secretome based approaches in Parkinson\u2019s disease regenerative medicine. Expert Opin Biol Ther. 2018;18(12):1235\u201345. https:\/\/doi.org\/10.1080\/14712598.2018.1546840.","journal-title":"Expert Opin Biol Ther."},{"issue":"1","key":"727_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S1474-4422(12)70295-8","volume":"12","author":"RA Barker","year":"2013","unstructured":"Barker RA, Barrett J, Mason SL, Bjorklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson\u2019s disease. Lancet Neurol. 2013;12(1):84\u201391. https:\/\/doi.org\/10.1016\/S1474-4422(12)70295-8.","journal-title":"Lancet Neurol."},{"issue":"1","key":"727_CR11","doi-asserted-by":"publisher","first-page":"ev.156117","DOI":"10.1242\/dev.156117","volume":"145","author":"M Parmar","year":"2018","unstructured":"Parmar M. Towards stem cell based therapies for Parkinson\u2019s disease. Development. 2018;145(1):ev.156117. https:\/\/doi.org\/10.1242\/dev.156117.","journal-title":"Development."},{"issue":"2","key":"727_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3124","volume":"33","author":"JA Steinbeck","year":"2015","unstructured":"Steinbeck JA, Choi SJ, Mrejeru A, Ganat Y, Deisseroth K, Sulzer D, et al. Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson\u2019s disease model. Nat Biotechnol. 2015;33(2):204\u20139. https:\/\/doi.org\/10.1038\/nbt.3124.","journal-title":"Nat Biotechnol"},{"issue":"7378","key":"727_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10648","volume":"480","author":"S Kriks","year":"2011","unstructured":"Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson\u2019s disease. Nature. 2011;480(7378):547\u201351. https:\/\/doi.org\/10.1038\/nature10648.","journal-title":"Nature"},{"issue":"3","key":"727_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.stem.2015.01.018","volume":"16","author":"PJ Hallett","year":"2015","unstructured":"Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson\u2019s disease. Cell Stem Cell. 2015;16(3):269\u201374. https:\/\/doi.org\/10.1016\/j.stem.2015.01.018.","journal-title":"Cell Stem Cell"},{"issue":"13","key":"727_CR15","doi-asserted-by":"publisher","first-page":"3462\u201373.e5","DOI":"10.1016\/j.celrep.2019.08.058","volume":"28","author":"AF Adler","year":"2019","unstructured":"Adler AF, Cardoso T, Nolbrant S, Mattsson B, Hoban DB, Jarl U, et al. hESC-derived dopaminergic transplants integrate into basal ganglia circuitry in a preclinical model of Parkinson\u2019s disease. Cell Rep. 2019;28(13):3462\u201373.e5. https:\/\/doi.org\/10.1016\/j.celrep.2019.08.058.","journal-title":"Cell Rep."},{"issue":"20","key":"727_CR16","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1212\/WNL.0b013e3181c1ded6","volume":"73","author":"NI Bohnen","year":"2009","unstructured":"Bohnen NI, Muller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73(20):1670\u20136. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c1ded6.","journal-title":"Neurology."},{"key":"727_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/bs.irn.2018.07.027","volume":"141","author":"NI Bohnen","year":"2018","unstructured":"Bohnen NI, Kanel P, Muller M. Molecular imaging of the cholinergic system in Parkinson\u2019s disease. Int Rev Neurobiol. 2018;141:211\u201350. https:\/\/doi.org\/10.1016\/bs.irn.2018.07.027.","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"727_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0165-3806(88)90027-2","volume":"467","author":"P Brundin","year":"1988","unstructured":"Brundin P, Barbin G, Strecker RE, Isacson O, Prochiantz A, Bjorklund A. Survival and function of dissociated rat dopamine neurones grafted at different developmental stages or after being cultured in vitro. Brain Res. 1988;467(2):233\u201343. https:\/\/doi.org\/10.1016\/0165-3806(88)90027-2.","journal-title":"Brain Res"},{"issue":"1\u20132","key":"727_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/0006-8993(86)91316-8","volume":"366","author":"P Brundin","year":"1986","unstructured":"Brundin P, Isacson O, Gage FH, Prochiantz A, Bjorklund A. The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting. Brain Res. 1986;366(1\u20132):346\u20139. https:\/\/doi.org\/10.1016\/0006-8993(86)91316-8.","journal-title":"Brain Res"},{"issue":"1","key":"727_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/bf00243848","volume":"65","author":"P Brundin","year":"1986","unstructured":"Brundin P, Nilsson OG, Strecker RE, Lindvall O, Astedt B, Bjorklund A. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson\u2019s disease. Exp Brain Res. 1986;65(1):235\u201340. https:\/\/doi.org\/10.1007\/bf00243848.","journal-title":"Exp Brain Res"},{"issue":"4393","key":"727_CR21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.571147","volume":"204","author":"MJ Perlow","year":"1979","unstructured":"Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science. 1979;204(4393):643\u20137. https:\/\/doi.org\/10.1126\/science.571147.","journal-title":"Science"},{"issue":"3","key":"727_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0006-8993(79)90472-4","volume":"177","author":"A Bjorklund","year":"1979","unstructured":"Bjorklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res. 1979;177(3):555\u201360. https:\/\/doi.org\/10.1016\/0006-8993(79)90472-4.","journal-title":"Brain Res"},{"issue":"4942","key":"727_CR23","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1126\/science.2105529","volume":"247","author":"O Lindvall","year":"1990","unstructured":"Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson\u2019s disease. Science. 1990;247(4942):574\u20137.","journal-title":"Science"},{"issue":"6","key":"727_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archneur.1989.00520420033021","volume":"46","author":"O Lindvall","year":"1989","unstructured":"Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson\u2019s disease: a detailed account of methodology and a 6-month follow-up. Arch Neurol. 1989;46(6):615\u201331.","journal-title":"Arch Neurol"},{"issue":"1","key":"727_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0006-8993(84)90541-9","volume":"297","author":"I Stromberg","year":"1984","unstructured":"Stromberg I, Herrera-Marschitz M, Hultgren L, Ungerstedt U, Olson L. Adrenal medullary implants in the dopamine-denervated rat striatum. I. Acute catecholamine levels in grafts and host caudate as determined by HPLC-electrochemistry and fluorescence histochemical image analysis. Brain Res. 1984;297(1):41\u201351. https:\/\/doi.org\/10.1016\/0006-8993(84)90541-9.","journal-title":"Brain Res."},{"issue":"1","key":"727_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0006-8993(84)90542-0","volume":"297","author":"M Herrera-Marschitz","year":"1984","unstructured":"Herrera-Marschitz M, Stromberg I, Olsson D, Ungerstedt U, Olson L. Adrenal medullary implants in the dopamine-denervated rat striatum. II. Acute behavior as a function of graft amount and location and its modulation by neuroleptics. Brain Res. 1984;297(1):53\u201361. https:\/\/doi.org\/10.1016\/0006-8993(84)90542-0.","journal-title":"Brain Res."},{"issue":"3","key":"727_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/0014-4886(84)90211-5","volume":"84","author":"JM Morihisa","year":"1984","unstructured":"Morihisa JM, Nakamura RK, Freed WJ, Mishkin M, Wyatt RJ. Adrenal medulla grafts survive and exhibit catecholamine-specific fluorescence in the primate brain. Exp Neurol. 1984;84(3):643\u201353. https:\/\/doi.org\/10.1016\/0014-4886(84)90211-5.","journal-title":"Exp Neurol"},{"issue":"6","key":"727_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJM198902093200601","volume":"320","author":"CG Goetz","year":"1989","unstructured":"Goetz CG, Olanow CW, Koller WC, Penn RD, Cahill D, Morantz R, et al. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson\u2019s disease. N Engl J Med. 1989;320(6):337\u201341. https:\/\/doi.org\/10.1056\/NEJM198902093200601.","journal-title":"N Engl J Med"},{"issue":"14","key":"727_CR29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1056\/NEJM198704023161402","volume":"316","author":"I Madrazo","year":"1987","unstructured":"Madrazo I, Drucker-Colin R, Diaz V, Martinez-Mata J, Torres C, Becerril JJ. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson\u2019s disease. N Engl J Med. 1987;316(14):831\u20134. https:\/\/doi.org\/10.1056\/NEJM198704023161402.","journal-title":"N Engl J Med"},{"issue":"2","key":"727_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ana.410310206","volume":"31","author":"O Lindvall","year":"1992","unstructured":"Lindvall O, Widner H, Rehncrona S, Brundin P, Odin P, Gustavii B, et al. Transplantation of fetal dopamine neurons in Parkinson\u2019s disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol. 1992;31(2):155\u201365. https:\/\/doi.org\/10.1002\/ana.410310206.","journal-title":"Ann Neurol"},{"issue":"5","key":"727_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/archneur.1990.00530050021007","volume":"47","author":"CR Freed","year":"1990","unstructured":"Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Wells TH, Barrett JN, et al. Transplantation of human fetal dopamine cells for Parkinson\u2019s disease: results at 1 year. Arch Neurol. 1990;47(5):505\u201312. https:\/\/doi.org\/10.1001\/archneur.1990.00530050021007.","journal-title":"Arch Neurol"},{"issue":"22","key":"727_CR32","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1056\/NEJM199211263272202","volume":"327","author":"CR Freed","year":"1992","unstructured":"Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi JX, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46\u00a0months after transplantation for Parkinson\u2019s disease. N Engl J Med. 1992;327(22):1549\u201355. https:\/\/doi.org\/10.1056\/NEJM199211263272202.","journal-title":"N Engl J Med"},{"key":"727_CR33","first-page":"17","volume":"58","author":"H Molina","year":"1993","unstructured":"Molina H, Quinones R, Ortega I, Alvarez L, Munoz J, Gonzalez C, et al. Computer assisted CT-guided stereotactic transplantation of foetal ventral mesencephalon to the caudate nucleus and putamen in Parkinson\u2019s disease. Acta Neurochir Suppl (Wien). 1993;58:17\u20139.","journal-title":"Acta Neurochir Suppl (Wien)."},{"issue":"22","key":"727_CR34","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJM199211263272201","volume":"327","author":"DD Spencer","year":"1992","unstructured":"Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranth C, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson\u2019s disease. N Engl J Med. 1992;327(22):1541\u20138. https:\/\/doi.org\/10.1056\/NEJM199211263272201.","journal-title":"N Engl J Med"},{"issue":"Pt 3","key":"727_CR35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/brain\/117.3.487","volume":"117","author":"M Peschanski","year":"1994","unstructured":"Peschanski M, Defer G, N\u2019Guyen JP, Ricolfi F, Monfort JC, Remy P, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson\u2019s disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain. 1994;117(Pt 3):487\u201399.","journal-title":"Brain"},{"issue":"3","key":"727_CR36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3171\/jns.2002.96.3.0589","volume":"96","author":"I Mendez","year":"2002","unstructured":"Mendez I, Dagher A, Hong M, Gaudet P, Weerasinghe S, McAlister V, et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg. 2002;96(3):589\u201396. https:\/\/doi.org\/10.3171\/jns.2002.96.3.0589.","journal-title":"J Neurosurg."},{"issue":"9","key":"727_CR37","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nrneurol.2015.123","volume":"11","author":"RA Barker","year":"2015","unstructured":"Barker RA, Drouin-Ouellet J, Parmar M. Cell-based therapies for Parkinson disease-past insights and future potential. Nat Rev Neurol. 2015;11(9):492\u2013503. https:\/\/doi.org\/10.1038\/nrneurol.2015.123.","journal-title":"Nat Rev Neurol."},{"issue":"1","key":"727_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ana.410420115","volume":"42","author":"GK Wenning","year":"1997","unstructured":"Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson\u2019s disease. Ann Neurol. 1997;42(1):95\u2013107. https:\/\/doi.org\/10.1002\/ana.410420115.","journal-title":"Ann Neurol"},{"issue":"Pt 6","key":"727_CR39","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/brain\/122.6.1121","volume":"122","author":"P Hagell","year":"1999","unstructured":"Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, et al. Sequential bilateral transplantation in Parkinson\u2019s disease: effects of the second graft. Brain. 1999;122(Pt 6):1121\u201332.","journal-title":"Brain"},{"issue":"Pt 7","key":"727_CR40","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/brain\/123.7.1380","volume":"123","author":"P Brundin","year":"2000","unstructured":"Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson\u2019s disease. Brain. 2000;123(Pt 7):1380\u201390.","journal-title":"Brain"},{"issue":"1","key":"727_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamaneurol.2013.4749","volume":"71","author":"Z Kefalopoulou","year":"2014","unstructured":"Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M, et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 2014;71(1):83\u20137. https:\/\/doi.org\/10.1001\/jamaneurol.2013.4749.","journal-title":"JAMA Neurol."},{"issue":"6","key":"727_CR42","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.celrep.2014.05.027","volume":"7","author":"PJ Hallett","year":"2014","unstructured":"Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O. Long-term health of dopaminergic neuron transplants in Parkinson\u2019s disease patients. Cell Rep. 2014;7(6):1755\u201361. https:\/\/doi.org\/10.1016\/j.celrep.2014.05.027.","journal-title":"Cell Rep."},{"key":"727_CR43","unstructured":"Henchcliffe C, Carter J, Hanineva A, Kang Y, Babich J, Gollomp SM, et al. Clinical and neuroimaging outcomes up to 18\u00a0years after fetal tissue transplant for Parkinson\u2019s disease [abstract]. Mov Disord. 2016;31(Suppl. 2)."},{"issue":"10","key":"727_CR44","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"CR Freed","year":"2001","unstructured":"Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N Engl J Med. 2001;344(10):710\u20139. https:\/\/doi.org\/10.1056\/NEJM200103083441002.","journal-title":"N Engl J Med"},{"issue":"3","key":"727_CR45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.10720","volume":"54","author":"CW Olanow","year":"2003","unstructured":"Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease. Ann Neurol. 2003;54(3):403\u201314. https:\/\/doi.org\/10.1002\/ana.10720.","journal-title":"Ann Neurol"},{"issue":"1","key":"727_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2967\/jnumed.109.066811","volume":"51","author":"Y Ma","year":"2010","unstructured":"Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, et al. Dopamine cell implantation in Parkinson\u2019s disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med. 2010;51(1):7\u201315. https:\/\/doi.org\/10.2967\/jnumed.109.066811.","journal-title":"J Nucl Med"},{"issue":"13","key":"727_CR47","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/mds.23834","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, et al. Health-related quality-of-life scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord. 2011;26(13):2371\u201380. https:\/\/doi.org\/10.1002\/mds.23834.","journal-title":"Mov Disord"},{"issue":"12","key":"727_CR48","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00702-017-1799-3","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova N, Martinez-Martin P, Katunina E, Chaudhuri KR. Advanced Parkinson\u2019s or \u201ccomplex phase\u201d Parkinson\u2019s disease? Re-evaluation is needed. J Neural Transm (Vienna). 2017;124(12):1529\u201337. https:\/\/doi.org\/10.1007\/s00702-017-1799-3.","journal-title":"J Neural Transm (Vienna)"},{"key":"727_CR49","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/B978-0-444-59575-1.00007-7","volume":"200","author":"EL Lane","year":"2012","unstructured":"Lane EL, Winkler C. L-DOPA- and graft-induced dyskinesia following transplantation. Prog Brain Res. 2012;200:143\u201368. https:\/\/doi.org\/10.1016\/B978-0-444-59575-1.00007-7.","journal-title":"Prog Brain Res"},{"issue":"7","key":"727_CR50","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41591-019-0507-2","volume":"25","author":"RA Barker","year":"2019","unstructured":"Barker RA, TRANSEURO Consortium. Designing stem-cell-based dopamine cell replacement trials for Parkinson\u2019s disease. Nat Med. 2019;25(7):1045\u201353. https:\/\/doi.org\/10.1038\/s41591-019-0507-2.","journal-title":"Nat Med."},{"issue":"38","key":"727_CR51","doi-asserted-by":"publisher","first-page":"38ra46","DOI":"10.1126\/scitranslmed.3000976","volume":"2","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson\u2019s patients with neural transplants. Sci Transl Med. 2010;2(38):38ra46. https:\/\/doi.org\/10.1126\/scitranslmed.3000976.","journal-title":"Sci Transl Med."},{"issue":"2","key":"727_CR52","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3171\/jns.1985.62.2.0169","volume":"62","author":"EO Backlund","year":"1985","unstructured":"Backlund EO, Granberg PO, Hamberger B, Knutsson E, Martensson A, Sedvall G, et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism: first clinical trials. J Neurosurg. 1985;62(2):169\u201373. https:\/\/doi.org\/10.3171\/jns.1985.62.2.0169.","journal-title":"J Neurosurg"},{"issue":"11","key":"727_CR53","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1212\/WNL.41.11.1719","volume":"41","author":"CG Goetz","year":"1991","unstructured":"Goetz CG, Stebbins GT 3rd, Klawans HL, Koller WC, Grossman RG, Bakay RA, et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology. 1991;41(11):1719\u201322.","journal-title":"Neurology."},{"issue":"3","key":"727_CR54","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/0014-4886(89)90032-0","volume":"104","author":"SL Stoddard","year":"1989","unstructured":"Stoddard SL, Ahlskog JE, Kelly PJ, Tyce GM, van Heerden JA, Zinsmeister AR, et al. Decreased adrenal medullary catecholamines in adrenal transplanted parkinsonian patients compared to nephrectomy patients. Exp Neurol. 1989;104(3):218\u201322.","journal-title":"Exp Neurol"},{"issue":"4","key":"727_CR55","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/ana.410290411","volume":"29","author":"JH Kordower","year":"1991","unstructured":"Kordower JH, Cochran E, Penn RD, Goetz CG. Putative chromaffin cell survival and enhanced host-derived TH-fiber innervation following a functional adrenal medulla autograft for Parkinson\u2019s disease. Ann Neurol. 1991;29(4):405\u201312. https:\/\/doi.org\/10.1002\/ana.410290411.","journal-title":"Ann Neurol"},{"issue":"8","key":"727_CR56","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1136\/jnnp.2006.106021","volume":"78","author":"A Minguez-Castellanos","year":"2007","unstructured":"Minguez-Castellanos A, Escamilla-Sevilla F, Hotton GR, Toledo-Aral JJ, Ortega-Moreno A, Mendez-Ferrer S, et al. Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. J Neurol Neurosurg Psychiatry. 2007;78(8):825\u201331. https:\/\/doi.org\/10.1136\/jnnp.2006.106021.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"727_CR57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1227\/01.neu.0000073315.88827.72","volume":"53","author":"V Arjona","year":"2003","unstructured":"Arjona V, Minguez-Castellanos A, Montoro RJ, Ortega A, Escamilla F, Toledo-Aral JJ, et al. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson\u2019s disease. Neurosurgery. 2003;53(2):321\u20138. https:\/\/doi.org\/10.1227\/01.neu.0000073315.88827.72(discussion 8\u201330).","journal-title":"Neurosurgery."},{"issue":"5","key":"727_CR58","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1212\/wnl.54.5.1042","volume":"54","author":"JM Schumacher","year":"2000","unstructured":"Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology. 2000;54(5):1042\u201350. https:\/\/doi.org\/10.1212\/wnl.54.5.1042.","journal-title":"Neurology."},{"issue":"2","key":"727_CR59","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/096368970000900212","volume":"9","author":"JS Fink","year":"2000","unstructured":"Fink JS, Schumacher JM, Ellias SL, Palmer EP, Saint-Hilaire M, Shannon K, et al. Porcine xenografts in Parkinson\u2019s disease and Huntington\u2019s disease patients: preliminary results. Cell Transplant. 2000;9(2):273\u20138. https:\/\/doi.org\/10.1177\/096368970000900212.","journal-title":"Cell Transplant"},{"issue":"3","key":"727_CR60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nm0397-350","volume":"3","author":"T Deacon","year":"1997","unstructured":"Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer P, Kott S, et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson\u2019s disease. Nat Med. 1997;3(3):350\u20133. https:\/\/doi.org\/10.1038\/nm0397-350.","journal-title":"Nat Med"},{"key":"727_CR61","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2741\/1217","volume":"9","author":"RA Bakay","year":"2004","unstructured":"Bakay RA, Raiser CD, Stover NP, Subramanian T, Cornfeldt ML, Schweikert AW, et al. Implantation of spheramine in advanced Parkinson\u2019s disease (PD). Front Biosci. 2004;9:592\u2013602. https:\/\/doi.org\/10.2741\/1217.","journal-title":"Front Biosci."},{"issue":"12","key":"727_CR62","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1001\/archneur.62.12.1833","volume":"62","author":"NP Stover","year":"2005","unstructured":"Stover NP, Bakay RA, Subramanian T, Raiser CD, Cornfeldt ML, Schweikert AW, et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch Neurol. 2005;62(12):1833\u20137. https:\/\/doi.org\/10.1001\/archneur.62.12.1833.","journal-title":"Arch Neurol"},{"issue":"2","key":"727_CR63","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.nurt.2008.02.006","volume":"5","author":"NP Stover","year":"2008","unstructured":"Stover NP, Watts RL. Spheramine for treatment of Parkinson\u2019s disease. Neurotherapeutics. 2008;5(2):252\u20139. https:\/\/doi.org\/10.1016\/j.nurt.2008.02.006.","journal-title":"Neurotherapeutics."},{"issue":"6","key":"727_CR64","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1474-4422(11)70097-7","volume":"10","author":"RE Gross","year":"2011","unstructured":"Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2011;10(6):509\u201319. https:\/\/doi.org\/10.1016\/S1474-4422(11)70097-7.","journal-title":"Lancet Neurol."},{"issue":"14","key":"727_CR65","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1212\/WNL.0b013e3181bbff1c","volume":"73","author":"ES Farag","year":"2009","unstructured":"Farag ES, Vinters HV, Bronstein J. Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease. Neurology. 2009;73(14):1095\u2013102. https:\/\/doi.org\/10.1212\/WNL.0b013e3181bbff1c.","journal-title":"Neurology."},{"key":"727_CR66","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-4939-9007-8_4","volume":"1919","author":"R Gonzalez","year":"2019","unstructured":"Gonzalez R, Garitaonandia I, Semechkin A, Kern R. Derivation of neural stem cells from human parthenogenetic stem cells. Methods Mol Biol. 2019;1919:43\u201357. https:\/\/doi.org\/10.1007\/978-1-4939-9007-8_4.","journal-title":"Methods Mol Biol"},{"issue":"11","key":"727_CR67","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3727\/096368916X691682","volume":"25","author":"R Gonzalez","year":"2016","unstructured":"Gonzalez R, Garitaonandia I, Poustovoitov M, Abramihina T, McEntire C, Culp B, et al. Neural stem cells derived from human parthenogenetic stem cells engraft and promote recovery in a nonhuman primate model of Parkinson\u2019s disease. Cell Transplant. 2016;25(11):1945\u201366. https:\/\/doi.org\/10.3727\/096368916X691682.","journal-title":"Cell Transplant"},{"issue":"4","key":"727_CR68","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3727\/096368915X687769","volume":"24","author":"R Gonzalez","year":"2015","unstructured":"Gonzalez R, Garitaonandia I, Crain A, Poustovoitov M, Abramihina T, Noskov A, et al. Proof of concept studies exploring the safety and functional activity of human parthenogenetic-derived neural stem cells for the treatment of Parkinson\u2019s disease. Cell Transplant. 2015;24(4):681\u201390. https:\/\/doi.org\/10.3727\/096368915X687769.","journal-title":"Cell Transplant"},{"key":"727_CR69","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/srep01463","volume":"3","author":"R Gonzalez","year":"2013","unstructured":"Gonzalez R, Garitaonandia I, Abramihina T, Wambua GK, Ostrowska A, Brock M, et al. Deriving dopaminergic neurons for clinical use: a practical approach. Sci Rep. 2013;3:1463. https:\/\/doi.org\/10.1038\/srep01463.","journal-title":"Sci Rep."},{"issue":"14","key":"727_CR70","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1089\/scd.2018.0001","volume":"27","author":"I Garitaonandia","year":"2018","unstructured":"Garitaonandia I, Gonzalez R, Sherman G, Semechkin A, Evans A, Kern R. Novel approach to stem cell therapy in Parkinson\u2019s disease. Stem Cells Dev. 2018;27(14):951\u20137. https:\/\/doi.org\/10.1089\/scd.2018.0001.","journal-title":"Stem Cells Dev."},{"issue":"15 Suppl.","key":"727_CR71","doi-asserted-by":"crossref","first-page":"P1.8-016","DOI":"10.1212\/WNL.92.15_supplement.P1.8-016","volume":"92","author":"R Kern","year":"2019","unstructured":"Kern R, Garitaonandia I, Gonzalez R, Sherman G, Semechkin A, Braine E, Nair G, Evans A. Results of an open label, dose escalating, phase 1 clinical trial evaluating the safety of a human neural stem cell based therapy in Parkinson\u2019s disease. Neurology. 2019;92(15 Suppl.):P1.8-016.","journal-title":"Neurology."},{"issue":"1","key":"727_CR72","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3233\/JPD-160798","volume":"6","author":"RA Barker","year":"2016","unstructured":"Barker RA, Parmar M, Kirkeby A, Bjorklund A, Thompson L, Brundin P. Are stem cell-based therapies for Parkinson\u2019s disease ready for the clinic in 2016? J Parkinsons Dis. 2016;6(1):57\u201363. https:\/\/doi.org\/10.3233\/JPD-160798.","journal-title":"J Parkinsons Dis."},{"issue":"1","key":"727_CR73","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.stemcr.2018.05.010","volume":"11","author":"YK Wang","year":"2018","unstructured":"Wang YK, Zhu WW, Wu MH, Wu YH, Liu ZX, Liang LM, et al. Human clinical-grade parthenogenetic ESC-derived dopaminergic neurons recover locomotive defects of nonhuman primate models of Parkinson\u2019s disease. Stem Cell Rep. 2018;11(1):171\u201382. https:\/\/doi.org\/10.1016\/j.stemcr.2018.05.010.","journal-title":"Stem Cell Rep."},{"issue":"5","key":"727_CR74","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861\u201372. https:\/\/doi.org\/10.1016\/j.cell.2007.11.019.","journal-title":"Cell"},{"issue":"3","key":"727_CR75","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nrm.2016.8","volume":"17","author":"K Takahashi","year":"2016","unstructured":"Takahashi K, Yamanaka S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol. 2016;17(3):183\u201393. https:\/\/doi.org\/10.1038\/nrm.2016.8.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"727_CR76","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nbt.1529","volume":"27","author":"SM Chambers","year":"2009","unstructured":"Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009;27(3):275\u201380. https:\/\/doi.org\/10.1038\/nbt.1529.","journal-title":"Nat Biotechnol"},{"key":"727_CR77","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/bs.pbr.2016.11.004","volume":"230","author":"J Takahashi","year":"2017","unstructured":"Takahashi J. Strategies for bringing stem cell-derived dopamine neurons to the clinic: the Kyoto trial. Prog Brain Res. 2017;230:213\u201326. https:\/\/doi.org\/10.1016\/bs.pbr.2016.11.004.","journal-title":"Prog Brain Res"},{"issue":"2","key":"727_CR78","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1172\/JCI130767","volume":"130","author":"B Song","year":"2020","unstructured":"Song B, Cha Y, Ko S, Jeon J, Lee N, Seo H, et al. Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson\u2019s disease models. J Clin Invest. 2020;130(2):904\u201320. https:\/\/doi.org\/10.1172\/JCI130767.","journal-title":"J Clin Invest."},{"key":"727_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-019-0257-7","author":"M Parmar","year":"2020","unstructured":"Parmar M, Grealish S, Henchcliffe C. The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci. 2020. https:\/\/doi.org\/10.1038\/s41583-019-0257-7.","journal-title":"Nat Rev Neurosci"},{"issue":"14","key":"727_CR80","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1089\/scd.2018.0107","volume":"27","author":"JF Loring","year":"2018","unstructured":"Loring JF. Autologous induced pluripotent stem cell-derived neurons to treat Parkinson\u2019s disease. Stem Cells Dev. 2018;27(14):958\u20139. https:\/\/doi.org\/10.1089\/scd.2018.0107.","journal-title":"Stem Cells Dev."},{"key":"727_CR81","unstructured":"\u2018Reprogrammed\u2019 stem cells implanted into patient with Parkinson\u2019s disease. Nature. 2018. https:\/\/www.nature.com\/articles\/d41586-018-07407-9. Accessed 4 Apr 2020."},{"key":"727_CR82","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/bs.pbr.2017.02.008","volume":"230","author":"L Studer","year":"2017","unstructured":"Studer L. Strategies for bringing stem cell-derived dopamine neurons to the clinic: the NYSTEM trial. Prog Brain Res. 2017;230:191\u2013212. https:\/\/doi.org\/10.1016\/bs.pbr.2017.02.008.","journal-title":"Prog Brain Res"},{"key":"727_CR83","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/bs.pbr.2016.11.011","volume":"230","author":"A Kirkeby","year":"2017","unstructured":"Kirkeby A, Parmar M, Barker RA. Strategies for bringing stem cell-derived dopamine neurons to the clinic: a European approach (STEM-PD). Prog Brain Res. 2017;230:165\u201390. https:\/\/doi.org\/10.1016\/bs.pbr.2016.11.011.","journal-title":"Prog Brain Res"},{"issue":"9","key":"727_CR84","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrn.2017.75","volume":"18","author":"JB Koprich","year":"2017","unstructured":"Koprich JB, Kalia LV, Brotchie JM. Animal models of alpha-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci. 2017;18(9):515\u201329. https:\/\/doi.org\/10.1038\/nrn.2017.75.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"727_CR85","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/mds.870070103","volume":"7","author":"JW Langston","year":"1992","unstructured":"Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7(1):2\u201313. https:\/\/doi.org\/10.1002\/mds.870070103.","journal-title":"Mov Disord"},{"issue":"4","key":"727_CR86","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/1531-8257(199907)14:4<572::aid-mds1005>3.0.co;2-c","volume":"14","author":"GL Defer","year":"1999","unstructured":"Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson\u2019s disease (CAPSIT-PD). Mov Disord. 1999;14(4):572\u201384. https:\/\/doi.org\/10.1002\/1531-8257(199907)14:4%3c572:aid-mds1005%3e3.0.co;2-c.","journal-title":"Mov Disord"},{"issue":"8","key":"727_CR87","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/14737175.2018.1503948","volume":"18","author":"R Pahwa","year":"2018","unstructured":"Pahwa R, Isaacson SH, Torres-Russotto D, Nahab FB, Lynch PM, Kotschet KE. Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson\u2019s disease: recommendations from an expert panel. Expert Rev Neurother. 2018;18(8):669\u201380. https:\/\/doi.org\/10.1080\/14737175.2018.1503948.","journal-title":"Expert Rev Neurother"},{"issue":"7","key":"727_CR88","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","volume":"368","author":"WM Schuepbach","year":"2013","unstructured":"Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. Neurostimulation for Parkinson\u2019s disease with early motor complications. N Engl J Med. 2013;368(7):610\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1205158.","journal-title":"N Engl J Med"},{"issue":"14","key":"727_CR89","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/mds.26024","volume":"29","author":"TA Mestre","year":"2014","unstructured":"Mestre TA, Espay AJ, Marras C, Eckman MH, Pollak P, Lang AE. Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson\u2019s disease: the EARLYSTIM trial: early is not always better. Mov Disord. 2014;29(14):1751\u20136. https:\/\/doi.org\/10.1002\/mds.26024.","journal-title":"Mov Disord"},{"key":"727_CR90","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/B978-0-444-59575-1.00010-7","volume":"200","author":"P Brundin","year":"2012","unstructured":"Brundin P, Kordower JH. Neuropathology in transplants in Parkinson\u2019s disease: implications for disease pathogenesis and the future of cell therapy. Prog Brain Res. 2012;200:221\u201341. https:\/\/doi.org\/10.1016\/B978-0-444-59575-1.00010-7.","journal-title":"Prog Brain Res"},{"issue":"Pt B","key":"727_CR91","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","volume":"298","author":"P Brundin","year":"2017","unstructured":"Brundin P, Dave KD, Kordower JH. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017;298(Pt B):225\u201335. https:\/\/doi.org\/10.1016\/j.expneurol.2017.10.003.","journal-title":"Exp Neurol"},{"key":"727_CR92","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.parkreldis.2018.10.025","volume":"59","author":"SP Sardi","year":"2019","unstructured":"Sardi SP, Simuni T. New Era in disease modification in Parkinson\u2019s disease: review of genetically targeted therapeutics. Parkinsonism Relat Disord. 2019;59:32\u20138. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.10.025.","journal-title":"Parkinsonism Relat Disord."},{"key":"727_CR93","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jconrel.2015.08.059","volume":"219","author":"KF Timbie","year":"2015","unstructured":"Timbie KF, Mead BP, Price RJ. Drug and gene delivery across the blood-brain barrier with focused ultrasound. J Control Release. 2015;219:61\u201375. https:\/\/doi.org\/10.1016\/j.jconrel.2015.08.059.","journal-title":"J Control Release"},{"key":"727_CR94","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/bs.pbr.2016.12.011","volume":"230","author":"AC Bachoud-Levi","year":"2017","unstructured":"Bachoud-Levi AC. From open to large-scale randomized cell transplantation trials in Huntington\u2019s disease: lessons from the multicentric intracerebral grafting in Huntington\u2019s disease trial (MIG-HD) and previous pilot studies. Prog Brain Res. 2017;230:227\u201361. https:\/\/doi.org\/10.1016\/bs.pbr.2016.12.011.","journal-title":"Prog Brain Res"},{"key":"727_CR95","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neuint.2017.01.016","volume":"106","author":"SV Precious","year":"2017","unstructured":"Precious SV, Zietlow R, Dunnett SB, Kelly CM, Rosser AE. Is there a place for human fetal-derived stem cells for cell replacement therapy in Huntington\u2019s disease? Neurochem Int. 2017;106:114\u201321. https:\/\/doi.org\/10.1016\/j.neuint.2017.01.016.","journal-title":"Neurochem Int"},{"issue":"6","key":"727_CR96","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.25354","volume":"84","author":"A Maxan","year":"2018","unstructured":"Maxan A, Mason S, Saint-Pierre M, Smith E, Ho A, Harrower T, et al. Outcome of cell suspension allografts in a patient with Huntington\u2019s disease. Ann Neurol. 2018;84(6):950\u20136. https:\/\/doi.org\/10.1002\/ana.25354.","journal-title":"Ann Neurol"},{"issue":"4","key":"727_CR97","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1212\/WNL.0000000000002889","volume":"87","author":"JD Glass","year":"2016","unstructured":"Glass JD, Hertzberg VS, Boulis NM, Riley J, Federici T, Polak M, et al. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology. 2016;87(4):392\u2013400. https:\/\/doi.org\/10.1212\/WNL.0000000000002889.","journal-title":"Neurology."},{"issue":"5","key":"727_CR98","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/WCO.0000000000000598","volume":"31","author":"RH Baloh","year":"2018","unstructured":"Baloh RH, Glass JD, Svendsen CN. Stem cell transplantation for amyotrophic lateral sclerosis. Curr Opin Neurol. 2018;31(5):655\u201361. https:\/\/doi.org\/10.1097\/WCO.0000000000000598.","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"727_CR99","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/jnnp-2012-302441","volume":"84","author":"RA Barker","year":"2013","unstructured":"Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2013;84(6):657\u201365. https:\/\/doi.org\/10.1136\/jnnp-2012-302441.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"727_CR100","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1212\/wnl.58.5.687","volume":"58","author":"RA Hauser","year":"2002","unstructured":"Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, et al. Bilateral human fetal striatal transplantation in Huntington\u2019s disease. Neurology. 2002;58(5):687\u201395. https:\/\/doi.org\/10.1212\/wnl.58.5.687.","journal-title":"Neurology."},{"issue":"1","key":"727_CR101","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ana.24174","volume":"76","author":"F Cicchetti","year":"2014","unstructured":"Cicchetti F, Lacroix S, Cisbani G, Vallieres N, Saint-Pierre M, St-Amour I, et al. Mutant hunting tin is present in neuronal grafts in Huntington disease patients. Ann Neurol. 2014;76(1):31\u201342. https:\/\/doi.org\/10.1002\/ana.24174.","journal-title":"Ann Neurol"},{"issue":"2","key":"727_CR102","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ana.410350208","volume":"35","author":"O Lindvall","year":"1994","unstructured":"Lindvall O, Sawle G, Widner H, Rothwell JC, Bjorklund A, Brooks D, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson\u2019s disease. Ann Neurol. 1994;35(2):172\u201380. https:\/\/doi.org\/10.1002\/ana.410350208.","journal-title":"Ann Neurol"},{"issue":"2","key":"727_CR103","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ana.410310207","volume":"31","author":"GV Sawle","year":"1992","unstructured":"Sawle GV, Bloomfield PM, Bjorklund A, Brooks DJ, Brundin P, Leenders KL, et al. Transplantation of fetal dopamine neurons in Parkinson\u2019s disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol. 1992;31(2):166\u201373. https:\/\/doi.org\/10.1002\/ana.410310207.","journal-title":"Ann Neurol"},{"issue":"Pt 1","key":"727_CR104","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/brain\/119.1.41","volume":"119","author":"GL Defer","year":"1996","unstructured":"Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P, et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain. 1996;119(Pt 1):41\u201350. https:\/\/doi.org\/10.1093\/brain\/119.1.41.","journal-title":"Brain."},{"issue":"3","key":"727_CR105","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ana.410380307","volume":"38","author":"TB Freeman","year":"1995","unstructured":"Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson\u2019s disease. Ann Neurol. 1995;38(3):379\u201388. https:\/\/doi.org\/10.1002\/ana.410380307.","journal-title":"Ann Neurol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00727-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-020-00727-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00727-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T17:20:26Z","timestamp":1722964826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-020-00727-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":105,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00727-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"29 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received by either author for the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr Henchcliffe has received honoraria for consulting for the California Institute of Regenerative Medicine (CIRM) Grant Working Group and research funding as an investigator in a research consortium from New York State Stem Cell Science (NYSTEM). Unrelated to this manuscript she has the following disclosures: honorarium for lecture from the Houston Methodist Neurological Institute; honoraria for ad hoc advisory board participation from US WorldMeds, Adamas Pharmaceuticals, Mitsubishi Tanabe Pharma Inc., and Prevail Therapeutics; and funding from the Michael J. Fox Foundation, National Institute of Health, Insightec, and Prevail Therapeutics. Dr H Sarva has received funding from the Michael J Fox Foundation, and clinical trial support from Biogen, Insightec and Lundbeck Pharmaceuticals. She has received honoraria for participation in advisory boards for Merz and Amneal pharmaceuticals, and for serving as an independent video rater for Neurocrine Neurosciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}